Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TRAVERE THERAPEUTICS, INC.

(TVTX)
  Bericht
Verzögert Nasdaq  -  22:00 23.09.2022
24.77 USD   +0.16%
23.08.Antrag von Vifor und Travere für Medikament gegen seltene Nierenkrankheiten wird in der EU geprüft
MT
15.08.TRAVERE THERAPEUTICS, INC. : Piper Sandler bekräftigt seine Kaufempfehlung
MM
08.08.TRAVERE THERAPEUTICS, INC. : Bewertung von HC Wainwright zum Kaufen erhalten
MM
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über TRAVERE THERAPEUTICS, INC.
15.09.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
14.09.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14.09.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29.08.TRAVERE THERAPEUTICS : Corporate Overview – August 2022
25.08.Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors..
23.08.Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU
22.08.TRAVERE THERAPEUTICS : Current Report - Form 8-K
22.08.TRAVERE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
22.08.BOURSE ZURICH : dans le rouge pour entamer la semaine
22.08.Travere, CSL Vifor Say European Medicines Agency has Accepted Marketing Authorization A..
22.08.CSL VIFOR : l'EMA accepte d'évaluer le dossier du sparsentan
22.08.Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional..
22.08.Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional..
17.08.TRAVERE THERAPEUTICS : Amendment to Current Report - Form 8-K/A
17.08.TRAVERE THERAPEUTICS, INC. Change in Directors or Principal Officers, Financial Statem..
17.08.Travere Therapeutics, Inc. Announces Executive Changes
12.08.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
11.08.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11.08.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04.08.TRAVERE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
04.08.Travere Therapeutics Q2 Non-GAAP Loss Widens, Revenue Slips; Shares Fall
04.08.TRANSCRIPT : Travere Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022
04.08.TRAVERE : Q2 Earnings Snapshot
04.08.TRAVERE THERAPEUTICS : Reports Second Quarter 2022 Financial Results - Form 8-K
04.08.Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q2 Revenue $54.2M
04.08.Travere Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
04.08.Travere Therapeutics Reports Second Quarter 2022 Financial Results
04.08.Travere Therapeutics Reports Second Quarter 2022 Financial Results
04.08.NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
03.08.Travere Therapeutics Provides Regulatory Updates on its Development Programs
03.08.Travere Therapeutics Provides Regulatory Updates on its Development Programs
28.07.Travere Therapeutics to Report Second Quarter 2022 Financial Results
13.07.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
12.07.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12.07.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14.06.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14.06.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02.06.Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
02.06.Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
23.05.TRAVERE THERAPEUTICS : Corporate Overview – May 2022
17.05.Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
16.05.TRAVERE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
16.05.Travere Therapeutics Says FDA Approves, Grants Priority Review for Sparsentan to Treat ..
16.05.Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Applicati..
16.05.Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Applicati..
16.05.Travere Therapeutics, Inc. Announces FDA Acceptance and Priority Review of New Drug App..
12.05.TRAVERE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matt..
11.05.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11.05.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11.05.TRANSCRIPT : Travere Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confer..
05.05.TRAVERE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
05.05.Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
05.05.TRAVERE : Q1 Earnings Snapshot
05.05.TRANSCRIPT : Travere Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
05.05.Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $48.5M, vs. Street Est of $..
05.05.Travere Therapeutics Reports First Quarter 2022 Financial Results
05.05.Travere Therapeutics Reports First Quarter 2022 Financial Results
03.05.Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
28.04.Travere Therapeutics to Report First Quarter 2022 Financial Results
28.04.Travere Therapeutics to Report First Quarter 2022 Financial Results
20.04.Travere Therapeutics Names Chris Cline CFO
20.04.TRAVERE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statemen..
20.04.Travere Therapeutics Announces Plan for Chief Financial Officer Transition
20.04.Travere Therapeutics, Inc. Announces Chief Financial Officer Changes
14.04.TRAVERE THERAPEUTICS : Corporate Overview – April 2022
13.04.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
12.04.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06.04.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disord..
21.03.TRAVERE THERAPEUTICS : Current Report (Form 8-K)
21.03.TRAVERE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
21.03.Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of I..
21.03.Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of I..
17.03.TRANSCRIPT : Travere Therapeutics, Inc. Presents at Barclays Global Healthcare Conference ..
17.03.TRAVERE THERAPEUTICS : Corporate Overview – March 2022
15.03.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
14.03.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11.03.TRAVERE THERAPEUTICS : Announces Proposed Convertible Senior Notes Offering - Form 8-K
11.03.TRAVERE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Dir..
09.03.Travere Therapeutics Prices Upsized $275 Million Senior Notes Offering
09.03.Travere Prices Upsized $275 Million Convertible Senior Notes Offering
09.03.Travere Prices Upsized $275 Million Convertible Senior Notes Offering
08.03.Travere Therapeutics Shares Drop 7% After Notes Offering Prices
08.03.Travere Therapeutics Plans Senior Note Offering -- Shares Decline
08.03.SECTOR UPDATE : Health Care Stocks Post Slight Gains Premarket Tuesday
08.03.Travere Therapeutics Plans $250 Million Senior Notes Offering
08.03.Travere Announces Proposed Convertible Senior Notes Offering
03.03.Travere Therapeutics to Present at the Barclays Global Healthcare Conference
28.02.Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People L..
24.02.TRAVERE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
24.02.Travere Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31..
24.02.TRAVERE THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results - Form ..
24.02.TRAVERE : Q4 Earnings Snapshot
24.02.TRANSCRIPT : Travere Therapeutics, Inc., Q4 2021 Earnings Call, Feb 24, 2022
24.02.Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
24.02.Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $57.2M, vs. Street Est of $..
24.02.Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
14.02.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10.02.Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
09.02.Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Confer..
13.01.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
Anstehende Termine für TRAVERE THERAPEUTICS, INC.